MAXCYTE INC. - COMMON STOCK

MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform

04 5 2023 08:05:53 提供 Nasdaq GlobeNewswire

MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023

12 4 2023 16:05:30 提供 Nasdaq GlobeNewswire

MaxCyte Appoints Douglas Swirsky as Chief Financial Officer

27 3 2023 16:05:00 提供 Nasdaq GlobeNewswire

MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results

15 3 2023 16:05:23 提供 Nasdaq GlobeNewswire

MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology

08 3 2023 08:00:01 提供 Nasdaq GlobeNewswire

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance

06 3 2023 16:05:00 提供 Nasdaq GlobeNewswire

MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences

01 2 2023 16:05:53 提供 Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs

03 1 2023 16:05:00 提供 Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases

05 12 2022 02:00:00 提供 Nasdaq GlobeNewswire

MaxCyte Reports Third Quarter 2022 Financial Results

09 11 2022 16:05:03 提供 Nasdaq GlobeNewswire

MaxCyte to Participate in Upcoming Investor Conferences

02 11 2022 08:05:00 提供 Nasdaq GlobeNewswire

MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022

12 10 2022 08:00:01 提供 Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program

28 9 2022 08:05:00 提供 Nasdaq GlobeNewswire

MaxCyte Debuts New State-of-the-Art Headquarters in Maryland’s I-270 Biotech Corridor

21 9 2022 08:05:00 提供 Nasdaq GlobeNewswire

MaxCyte to Participate in Morgan Stanley 20th Annual Global Healthcare Conference

07 9 2022 16:05:00 提供 Nasdaq GlobeNewswire

MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results

10 8 2022 16:05:01 提供 Nasdaq GlobeNewswire

MaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022

15 7 2022 08:00:00 提供 Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs

12 7 2022 08:00:01 提供 Nasdaq GlobeNewswire

MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 5 2022 16:30:00 提供 Nasdaq GlobeNewswire

MaxCyte Reports First Quarter Financial Results

09 5 2022 16:05:03 提供 Nasdaq GlobeNewswire